LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a ...

GBS occurrence was highest in the first 2 weeks after dengue symptom onset ...

Annexon, Inc. (ANNX) was able to achieve positive results from its phase 3 study for the treatment of patients with Guillain-Barré syndrome [GBS]. Matter of fact, it noted that a lower dose of its ...

In endemic areas, dengue-related Guillain-Barre syndrome could be a 'substantial and underrecognized component of the ...

Guillain-?Barr Syndrome is a rare condition in which a person's immune system attacks the peripheral nerves. People affected suffer from muscle weakness and paralysis. A research team led by ETH ...

BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...

Lucknow neuro physiotherapist Dr. Akanksha Upadhyay presented a case study on Guillain-Barré Syndrome rehabilitation at AIIMS Delhi. Her research detailed an 8-week physiotherapy program that ...

Real-world evidence study shows ANX005 improves muscle strength and functional outcomes in Guillain-Barré Syndrome compared to current treatments. Potential regulatory concerns may arise if the FDA ...

PUNE: The ninth casualty linked to Guillain-Barre Syndrome in Pune, a 34-year-old resident of Wagholi, showed symptoms that ...

Freddie Freeman's toddler Max Freeman is back home after spending eight days in the pediatric intensive care unit battling Guillain-Barre syndrome, a rare life-threatening form of paralysis. “Max ...

KYOTO, Japan — Eculizumab (Soliris, Alexion Pharmaceuticals) is safe for the treatment of patients with severe Guillain-Barré syndrome (GBS), a new phase 2 study shows. However, although more patients ...